TACE With Dicycloplatin(TP21) in Unresectable HCC

Hepatocellular Carcinoma Clinical Trial

Official title:

TACE With Dicycloplatin（TP21） in Patients With Unresectable Hepatocellular Carcinoma: an Open, Parallel-controlled,Multicenter Randomized Phase III Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05472896
• Other study ID #: TP21-TACE
• Status: Recruiting
• Phase: Phase 3
• Start date: June 9, 2022
• Est. completion date: June 30, 2024

Study information

• Verified date: July 2022
• Source: Zhongda Hospital
• Contact: Hai-Dong Zhu Doctor, Doctor
• Phone: 13851420979
• Email: zhuhaidong9509[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the effectiveness and safety of TP21 injection for TACE in treatment of hepatocellular carcinoma:

1. Primary efficacy endpoint: progression-free survival (PFS), which will be assessed by the Independent Review Committee according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST).

2. Secondary efficacy endpoints: PFS, objective response rate (ORR), disease control rate (DCR), overall survival (OS), time to progression (TTP), 1-year progression-free survival, 1-year survival and 2-year survival assessed by the investigator.

Description:

TP21 injection is a supramolecular compound that has completed early pharmacological and toxicological preclinical studies, as well as phase I and II clinical studies. Data from previous studies showed that TP21 injection has significant advantages over traditional platinum-based drugs in terms of broad spectrum, low toxicity, high efficacy and low drug resistance etc. The results of the Phase II TACE clinical exploratory study in hepatocellular carcinoma showed a trend for TP21 alone to be significantly better than epirubicin alone, and due to the small sample size, the available data were insufficient to demonstrate obvious advantage of this drug. Now, a confirmatory phase III clinical study of TACE for hepatocellular carcinoma is needed, which may continue to adopt the main design of the phase II clinical trial, in a single agent comparison form: all the subjects will be randomized 1:1 into TP21+lipiodol group (trial group), and epirubicin hydrochloride+lipiodol group (control group) to receive TACE treatment of either "TP21+lipiodol" or "epirubicin hydrochloride+lipiodol". TACE treatment should be carried out for no more than 3 times in half a year to no more than 5 times within 1 year, and about 332 subjects will be enrolled, 166 for the trial group and the control group each.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 332
• Est. completion date: June 30, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. age 18 years or older, and life expectancy = 3 months;

2. histopathologically or clinically confirmed HCC;

3. Child-Pugh class A or B liver function (=7 level), Eastern Cooperative Oncology Group performance status (PS) score of 0, 1 or 2;

4. China Liver Cancer stage IIb, IIIa (only Cheng's classification type I:portal vein tumor thrombus invading the portal vein branches of the liver lobe or liver segment) , and Ib, 2a patients who can be surgically removed, but are unable or unwilling to undergo surgery due to other reasons (such as advanced age, severe liver cirrhosis, etc.);

5. at least one lesion measurable by modified Response Evaluation Criteria in Solid Tumors for HCC (mRECIST);

6. no history of TACE or tumor recurrence after curative-intent therapy (i.e., surgical resection or ablation);

7. No blood transfusion and blood products, no use of granulocyte colony-stimulating factor (GCSF) and other hematopoietic stimulating factors within 2 weeks before screening; Hemoglobin = 80g/L;Platelet count = 60×10^9 /L; White blood cell count = 3×10^9/L; Alanine aminotransferase = 3 times the upper limit of normal; Aspartate aminotransferase = 3×times the upper limit of normal; Serum creatinine Cr = 1.5×times the upper limit of normal;

Exclusion Criteria:

1. allergic to platinum or iodine products or epirubicin and related excipients;

2. diffuse HCC (whole liver tumor burden = 70%),and the hepatocellular carcinoma is hypovascular;

3. first-order branches and distant of the portal vein tumor thrombus;

4. Liver function classification is Child Pugh C;

5. Invasion of left and right hepatic duct, common hepatic duct, cystic duct and common bile duct;

6. The tumor has severe arteriovenous shunt, which the investigator judges may affect the efficacy of TACE; or there is extrahepatic metastasis;

7. Patients with other tumors, except for thyroid tumors and skin carcinoma in situ that have been cured, early cervical cancer;

8. Have a history of gastrointestinal bleeding or a marked tendency to gastrointestinal bleeding within 6 months before randomization;

9. Uncorrectable abnormal coagulation function or bleeding tendency;

10. received other antitumor therapies within the past 4 weeks (e.g., chemotherapy, radiotherapy, immunotherapy,Chinese medicine with antitumor effect), or received the above anti-tumor drugs within 5 half-lives;

11. received immunotherapy, targeted therapy or radiotherapy for intrahepatic tumors

12. have received an organ transplant

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Procedure:
• cTACE
transcatheter arterial chemoembolization with

Drug:
• Dicycloplatin (TP21)
the dosage of dicycloplatin was based on the body surface area (550 mg/m2) according to previous research. The volume ratio of lipiodol to dicycloplatin aqueous solution was 1:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.
• Epirubicin
the dosage of epirubicin was determined according to the tumor size, and the maximum dose was limited to 40 mg. The volume ratio of lipiodol to epirubicin aqueous solution was 2:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.

Locations

Country	Name	City	State
China	Zhongda Hospital, Southeast University	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Gao-jun Teng

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adverse event/ serious adverse event		Up to ~2years
Primary	Progression-free survival (PFS) by Independent Review Committee	Progression-free survival (PFS) by Independent Review Committee (IRC) according to the Modified Response Evaluation Criteria in Solid Tumors (mRECIST).	Up to ~1 years
Secondary	Progression-free survival (PFS) by investigator	Progression-free survival (PFS) by investigator according to the Modified Response Evaluation Criteria in Solid Tumors (mRECIST).	Up to ~1 years
Secondary	Objective Response Rate (ORR)		Up to ~1 years
Secondary	Disease Control Rate (DCR)		Up to ~1 years
Secondary	Overall Survival (OS)		Up to ~3 years
Secondary	Time To Progress (TTP)		Up to ~3 years
Secondary	1 year progression-free survival rate		Up to ~1 years
Secondary	1 year survival rate		Up to ~1 years
Secondary	2 year survival rate		Up to ~2years